Physician profile
Ossama Maher
NPI 1245663087
$5,989.08
in general payments reported to CMS, 2019-2025
27 companies · $4,282 in 2025
The $4,282 reported for 2025 was more than what 78% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $39.52 · 2021: $144 · 2022: $53.75 · 2023: $486 · 2024: $648 · 2025: $4,282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $2,998 · Food and Beverage: $2,195 · Consulting Fee: $175 · Education: $47.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $2,997.50 |
| Food and Beverage | $2,194.87 |
| Consulting Fee | $175.00 |
| Education | $47.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Day One Biopharmaceuticals | $3,102.05 | 2024-2025 | Ojemda |
| Novartis Pharmaceuticals Corporation | $898.47 | 2019-2025 | |
| Sobi, INC | $518.55 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $287.56 | 2023-2025 | Ultomiris, Koselugo |
| Sanofi-Aventis U.S. LLC | $149.82 | 2025 | |
| Incyte Corporation | $146.82 | 2025 | Niktimvo, Niktimvo |
| Astellas Pharma US INC | $117.20 | 2024-2025 | Cresemba |
| Bayer Healthcare Pharmaceuticals INC. | $98.13 | 2019-2024 | |
| Novo Nordisk INC | $93.07 | 2022-2025 | Alhemo, Novoeight, Rebinyn |
| Springworks Therapeutics, INC. | $80.37 | 2025 | Gomekli |
| Amgen INC. | $61.61 | 2019 | |
| Genetix Biotherapeutics INC | $51.56 | 2024 | |
| Genentech USA, INC. | $45.52 | 2023-2024 | Hemlibra |
| Takeda Pharmaceuticals U.S.A., INC. | $42.94 | 2023-2025 | Vpriv |
| Rare Disease Therapeutics, INC. | $42.66 | 2025 | Xromi |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $38.34 | 2024 | |
| Hema Biologics, LLC | $35.61 | 2024-2025 | Sevenfact, Sevenfact |
| Mesoblast, INC. | $31.12 | 2025 | Ryoncil |
| Y-Mabs Therapeutics, INC. | $23.42 | 2025 | Danyelza |
| Jazz Pharmaceuticals INC. | $22.50 | 2025 | |
| Uswm, LLC | $21.06 | 2025 | Iwilfin |
| Genzyme Corporation | $17.50 | 2023 | |
| Recordati_rare_diseases_inc. | $16.94 | 2024 | Panhematin |
| Agios Pharmaceuticals, INC. | $16.89 | 2024 | Pyrukynd |
| Btg International INC. | $15.56 | 2024 | |
| Janssen Biotech, INC. | $13.81 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ossama Maher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.